S
Sequana Medical
Developing implantable and drug-based solutions to treat fluid overload in advanced liver and heart disease
About Sequana Medical
Sequana Medical is a medical technology company that develops implantable and drug-based treatments for fluid overload in patients with liver disease, heart failure, and certain cancers. The company focuses on addressing cases where standard diuretic therapies are no longer effective.
The company’s main product, the alfapump®, is an implantable device that automatically transfers excess fluid from the abdominal cavity (ascites) to the bladder, where it is naturally excreted by the body. This system is designed for patients with liver disease who experience recurrent fluid build-up, helping to reduce the need for repeated hospital visits and manual fluid removal procedures.
Sequana Medical is also developing Direct Sodium Removal (DSR®) therapy, a drug-based method that aims to reduce fluid overload by removing sodium from the body. This approach is being studied primarily for patients with heart failure who are resistant to conventional diuretic treatments.
With ongoing clinical studies and regulatory development, Sequana Medical is working to expand access to its technologies and provide new options for patients with limited treatment alternatives.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2006
- Headquarters
- Ghent, Belgium
- Listing
- IPO 2019
- Employees
- 62
- Open positions
- None listed
- Dealroom signal
- 85.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Oncology, Cardiology and cardiovascular
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Apr 2025 | $0 | — | Global Emerging Markets | ↗ |
| POST IPO CONVERTIBLE✓Other financing | Mar 2025 | $6.9M | — | SFPIM | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Sequana Medical is 8.4K monthly website visits, up 127% over the last three months. Sequana Medical's team grew 5.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sequana Medical in the Ghent ecosystem
The Sequana Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Entrepreneurs Fund
BioMedVC
Capricorn Partners
Rosetta Capital
Partners in Equity (PiE)- SESensinnovat
EQT Group
Series B and later8 investors entered at this stage
EQT Life Sciences
VI Partners
NeoMed
PMV
Newton BioCapital
SFPIM
Kreos Capital
Global Emerging Markets
Other known investors1 additional known investor
Bootstrap Europe
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sequana Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sequana Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








